Journal article · 2023
Abstract B055: Characterization of highly selective and CNS-penetrant PARP1 inhibitors
Molecular Cancer Therapeutics, 22(12_Supplement), B055 · Published 1 December 2023 · DOI 10.1158/1535-7163.targ-23-b055
In brief
“Abstract B055: Characterization of highly selective and CNS-penetrant PARP1 inhibitors” is a 2023 journal article by Phillip M. Cowley and 3 co-authors, published in Molecular Cancer Therapeutics. OpenAlex counts 0 citations as of 19 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 0
- Authors
- 4
Abstract
First-generation PARP1/2 inhibitors are FDA-approved for cancers such as breast, ovarian prostate and pancreas and provide significant therapeutic benefit to patients whose tumors harbor BRCA1 or BRCA2 mutations or homologous recombination deficiency (HRD). However, their use is associated with hematological toxicities that narrow their therapeutic index and restrict their application, particularly in combination with standard-of-care… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Cowley, P. M., McGuinness, B. E., Campbell, G. M., & Wise, A. (2023). Abstract B055: Characterization of highly selective and CNS-penetrant PARP1 inhibitors. Molecular Cancer Therapeutics, 22(12_Supplement), B055. https://doi.org/10.1158/1535-7163.targ-23-b055
MLA 9
Cowley, Phillip M., et al. “Abstract B055: Characterization of highly selective and CNS-penetrant PARP1 inhibitors.” Molecular Cancer Therapeutics, vol. 22, no. 12_Supplement, 2023, p. B055. https://doi.org/10.1158/1535-7163.targ-23-b055.
Chicago
Cowley, Phillip M., Barry E. McGuinness, Gillian M. Campbell, and Alan Wise. 2023. “Abstract B055: Characterization of highly selective and CNS-penetrant PARP1 inhibitors.” Molecular Cancer Therapeutics 22 (12_Supplement): B055. https://doi.org/10.1158/1535-7163.targ-23-b055.
Harvard
Cowley, P. M. et al. (2023) ‘Abstract B055: Characterization of highly selective and CNS-penetrant PARP1 inhibitors’, Molecular Cancer Therapeutics, 22(12_Supplement), p. B055. doi:10.1158/1535-7163.targ-23-b055.
IEEE
P. M. Cowley, B. E. McGuinness, G. M. Campbell, and A. Wise, “Abstract B055: Characterization of highly selective and CNS-penetrant PARP1 inhibitors,” Molecular Cancer Therapeutics, vol. 22, no. 12_Supplement, p. B055, 2023, doi: 10.1158/1535-7163.targ-23-b055.
BibTeX
@article{cowley2023abstract,
title = {{Abstract B055: Characterization of highly selective and CNS-penetrant PARP1 inhibitors}},
author = {Cowley, Phillip M. and McGuinness, Barry E. and Campbell, Gillian M. and Wise, Alan},
journal = {Molecular Cancer Therapeutics},
year = {2023},
volume = {22},
number = {12_Supplement},
pages = {B055},
doi = {10.1158/1535-7163.targ-23-b055},
url = {https://doi.org/10.1158/1535-7163.targ-23-b055}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- PARP-1 inhibitors
- hematologic toxicity
- homologous recombination deficiency
- ATR inhibitors
- ATM deficiency
- CNS penetration
- poly(ADP-ribosyl)ation
- PK/PD relationship
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Cowley, P. M., McGuinness, B. E., Campbell, G. M., & Wise, A. (2023). Abstract B055: Characterization of highly selective and CNS-penetrant PARP1 inhibitors. Molecular Cancer Therapeutics, 22(12_Supplement), B055. https://doi.org/10.1158/1535-7163.targ-23-b055
How many times has this paper been cited?
0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Phillip M. Cowley, Barry E. McGuinness, Gillian M. Campbell, Alan Wise.
What is the DOI of this paper?
10.1158/1535-7163.targ-23-b055, permanently at https://doi.org/10.1158/1535-7163.targ-23-b055. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.